The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
Open accessPublished version of a preprint
Abstract
The infection of a novel coronavirus found in Wuhan of China (2019-nCoV) is rapidly spreading, and the incidence rate is increasing worldwide. Due to the lack of effective treatment options for 2019-nCoV, various strategies are being tested in China, including drug repurposing. In this study, we used our pretrained deep learning-based drug-target interaction model called Molecule Transformer-Drug Target Interaction (MT-DTI) to identify commercially available drugs that could act on viral proteins of 2019-nCoV. The result showed that atazanavir, an antiretroviral medication used to treat and prevent the human immunodeficiency virus (HIV), is the best chemical compound, showing a inhibitory potency with K d of 94.94 nM against the 2019-nCoV 3C-like proteinase, followed by efavirenz (199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir, and darunavir are all designed to target viral proteinases. However, in our prediction, they may also bind to the replication complex components of 2019-nCoV with an inhibitory potency with K d < 1000 nM. In addition, we also found that several antiviral agents, such as Kaletra, could be used for the treatment of 2019-nCoV, although there is no real-world evidence supporting the prediction. Overall, we suggest that the list of antiviral drugs identified by the MT-DTI model should be considered, when establishing effective treatment strategies for 2019-nCoV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Open Babel: An open chemical toolbox
O'Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011) · Journal of Cheminformatics · doi:10.1186/1758-2946-3-33 · Cited by 10,939
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
First case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,735
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2223-y · Cited by 4,358
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,662
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities
Liu, T., Lin, Y., Wen, X., Jorissen, R. N., & Gilson, M. K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl999 · Cited by 2,124
DeepDTA: deep drug–target binding affinity prediction
Öztürk, H., Özgür, A., & Ozkirimli, E. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty593 · Cited by 1,696
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. M. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,645
Software for molecular docking: a review
Pagadala, N. S., Syed, K., & Tuszynski, J. (2017) · Biophysical Reviews · doi:10.1007/s12551-016-0247-1 · Cited by 1,522
Coronavirus avian infectious bronchitis virus
Cavanagh, D. (2007) · Veterinary Research · doi:10.1051/vetres:2006055 · Cited by 1,053
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome
Kuiken, T., Fouchier, R. A., Schutten, M., Rimmelzwaan, G. F., van Amerongen, G., van Riel, D., Laman, J. D., de Jong, T., van Doornum, G., Lim, W., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13967-0 · Cited by 1,020
Human Coronavirus: Host-Pathogen Interaction
Fung, T. S., & Liu, D. X. (2019) · Annual Review of Microbiology · doi:10.1146/annurev-micro-020518-115759 · Cited by 960
Coronavirus Genomics and Bioinformatics Analysis
Woo, P. C. Y., Huang, Y., Lau, S. K. P., & Yuen, K.-Y. (2010) · Viruses · doi:10.3390/v2081803 · Cited by 913
Weiss, S. R., & Leibowitz, J. L. (2011) · Advances in Virus Research · doi:10.1016/b978-0-12-385885-6.00009-2 · Cited by 896
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
Xu, J., Zhao, S., Teng, T., Abdalla, A. E., Zhu, W., Xie, L., Wang, Y., & Guo, X. (2020) · Viruses · doi:10.3390/v12020244 · Cited by 683
Tang, J., Szwajda, A., Shakyawar, S., Xu, T., Hintsanen, P., Wennerberg, K., & Aittokallio, T. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci400709d · Cited by 645
Human Coronaviruses: A Review of Virus–Host Interactions
Lim, Y., Ng, Y., Tam, J., & Liu, D. (2016) · Diseases · doi:10.3390/diseases4030026 · Cited by 591
Toward more realistic drug-target interaction predictions
Pahikkala, T., Airola, A., Pietila, S., Shakyawar, S., Szwajda, A., Tang, J., & Aittokallio, T. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbu010 · Cited by 559
Wang, Z., Chen, X., Lu, Y., Chen, F., & Zhang, W. (2020) · BioScience Trends · doi:10.5582/bst.2020.01030 · Cited by 544
He, T., Heidemeyer, M., Ban, F., Cherkasov, A., & Ester, M. (2017) · Journal of Cheminformatics · doi:10.1186/s13321-017-0209-z · Cited by 509
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Jolly, G. (2016) · TEXILA INTERNATIONAL JOURNAL OF PUBLIC HEALTH · doi:10.21522/tijph.2013.04.04.art033 · Cited by 441
More than 80 clinical trials launch to test coronavirus treatments
Maxmen, A. (2020) · Nature · doi:10.1038/d41586-020-00444-3 · Cited by 133
Self-Attention Based Molecule Representation for Predicting Drug-Target InteractionPreprint
Shin, B., Park, S. S., Kang, K., & Ho, J. C. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1908.06760 · Cited by 130
Self-citationTanoli, Z., Alam, Z., Vähä-Koskela, M. J. V., Ravikumar, B., Malyutina, A., Jaiswal, A., Tang, J. P., Wennerberg, K., & Aittokallio, T. A. (2018) · Database · doi:10.1093/database/bay083 · Cited by 80
Tran, T., & Kavuluru, R. (2018) · Database · doi:10.1093/database/bay092 · Cited by 42
Research works printed but not linked: 4
- Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M. et al: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; .
- Z. Jin X. Du Y. Xu Y. Deng M. Liu Z. Zhao et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. bioRxiv. 2020.
- Dayer M.R., Taleb-Gassabi S. and Dayer M.S.: Lopinavir; a potent drug against coronavirus infection: insight from molecular docking study. Arch Clin Infect Diseas 2017; 12: e13823. · doi:10.5812/archcid.13823
- Hopkins J.S.U.S.: drugmakers ship therapies to China, seeking to treat coronavirus. Wall Street J 2020; .
Cited by
Ciotti, M., Ciccozzi, M., Terrinoni, A., Jiang, W.-C., Wang, C.-B., & Bernardini, S. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1783198 · Cited by 1,514
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
“Beck et al. 2020 conducted a study to predict commercially available antiviral drugs as a potential therapeutic agent against novel coronavirus (SARS-CoV-2) through DeepDTA [316].”
BackgroundChamola, V., Hassija, V., Gupta, V., & Guizani, M. (2020) · IEEE Access · doi:10.1109/access.2020.2992341 · Cited by 1,099
COVID-19: Transmission, prevention, and potential therapeutic opportunities
Lotfi, M., Hamblin, M. R., & Rezaei, N. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.05.044 · Cited by 1,016
Lalmuanawma, S., Hussain, J., & Chhakchhuak, L. (2020) · Chaos, Solitons & Fractals · doi:10.1016/j.chaos.2020.110059 · Cited by 845
Metadata
- Authors
- Beck, B. R., Shin, B., Choi, Y., Park, S., & Kang, K.
- Venue
- Computational and Structural Biotechnology Journal
- Published
- 2020
- Volume
- 18
- Pages
- 784-790
- ISSN
- 2001-0370 (ISSN-L)
- OpenAlex
- W3012994592
- Cited by
- 816
- References
- 32
- FWCI
- 83.02
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 84 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.